Bristol-Myers was formed in 1887 when William McLaren Bristol and John Ripley Myers bought a small pharmaceutical firm in upstate New York. From the start, quality was a key focus of the Bristol-Myers organisation.

The Squibb Corporation was founded in Brooklyn almost 30 years earlier, by Dr. Edward Robinson Squibb in 1858. The company was dedicated to the production of “consistently pure medicines”.

The two firms developed in parallel for more than a century, before merging in 1989, creating a global leader in the health care industry.

		1967 We created our first anti-cancer medication, Hydrea® (hydroxycarbamide), which is still used today.				1994 Taxol® (paclitaxel) is heralded as a breakthrough anti-cancer medicine.
		1975 The Squibb Corporation created the first medicine in a new class of antihypertensive agents called ACE inhibitors.				1998 The cardiovascular medicine, Plavix® (clopidogrel), is launched in the UK by Bristol-Myers Squibb and sanofi-aventis.
		1991 Bristol-Myers Squibb developed the world’s second HIV medicine.				2004 Abilify® (aripiprazole) is launched. We also released Reyataz® (atazanavir) the first once-daily protease inhibitor and Perfalgan® the first intravenous paracetamol in this year.
		2006 Two medicines are launched, Baraclude® (entecavir) an anti-viral agent and Sprycel® (dasatinib) an anti-cancer medicine.